cinclus pharma header notes in audience


Check out the latest news from Cinclus Pharma

Cinclus Pharma at Redeye Investor Forum 2024

Christer Ahlberg, CEO of Cinclus Pharma, was invited to present the company's latest updates and the development of linaprazan glurate at the Redeye Investor Forum in Gothenburg on April 18, 2024.

Read more
Cinclus Pharma Webbnyhet 2540X1200

Cinclus Pharma announces positive FDA interaction

Cinclus Pharma today announces that the company has completed a successful so-called end-of-phase-II meeting, with the US Food and Drug Administration (FDA) for the indication erosive gastroesophageal reflux disease (eGERD). The FDA broadly accepted Cinclus Pharma's proposal for the phase III program, including study design and primary endpoint for the studies. The positive outcome allows Cinclus Pharma to proceed with its phase III program.

Read more
Cinclus News Research 65255460